{"title":"[Del(1p32) 在新诊断多发性骨髓瘤患者中的预后价值]。","authors":"Rui Guo, Xu-Xing Shen, Yuan Xia, Yuan-Yuan Jin, Jian-Yong Li, Li-Juan Chen, Hai-Rong Qiu","doi":"10.19746/j.cnki.issn.1009-2137.2024.03.017","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To analyze the prognostic value of del(1p32) in patients with newly diagnosed multiple myeloma (MM).</p><p><strong>Methods: </strong>The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed. Clinical characteristic combined with genetic features, especially del(1p32), were analyzed for survival and prognostic of patients.</p><p><strong>Results: </strong>Among the 341 patients with newly diagnosed MM, 24(7.0%) patients were del(1p32) positive. The progression-free survival (PFS) and overall survival (OS) were significantly shorter in MM patients with del(1p32) than those without del(1p32) (PFS: <i>P</i> < 0.001;OS: <i>P</i> < 0.001). The COX proportional-hazards model showed that del (1p32) was an independent risk factor for PFS and OS of patients with MM. The patients with both 1q21 gain/amplification and del(1p32), as \"double-hit chromosome 1\", have worse prognosis than those with only 1q21 gain/amplification or only del(1p32) (PFS: <i>P</i> < 0.001; OS: <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Del(1p32) is an independent risk factor for PFS and OS of patients with MM. Del(1p32) detection should be widely used in the prognostic analysis for newly diagnosed MM patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].\",\"authors\":\"Rui Guo, Xu-Xing Shen, Yuan Xia, Yuan-Yuan Jin, Jian-Yong Li, Li-Juan Chen, Hai-Rong Qiu\",\"doi\":\"10.19746/j.cnki.issn.1009-2137.2024.03.017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To analyze the prognostic value of del(1p32) in patients with newly diagnosed multiple myeloma (MM).</p><p><strong>Methods: </strong>The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed. Clinical characteristic combined with genetic features, especially del(1p32), were analyzed for survival and prognostic of patients.</p><p><strong>Results: </strong>Among the 341 patients with newly diagnosed MM, 24(7.0%) patients were del(1p32) positive. The progression-free survival (PFS) and overall survival (OS) were significantly shorter in MM patients with del(1p32) than those without del(1p32) (PFS: <i>P</i> < 0.001;OS: <i>P</i> < 0.001). The COX proportional-hazards model showed that del (1p32) was an independent risk factor for PFS and OS of patients with MM. The patients with both 1q21 gain/amplification and del(1p32), as \\\"double-hit chromosome 1\\\", have worse prognosis than those with only 1q21 gain/amplification or only del(1p32) (PFS: <i>P</i> < 0.001; OS: <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>Del(1p32) is an independent risk factor for PFS and OS of patients with MM. Del(1p32) detection should be widely used in the prognostic analysis for newly diagnosed MM patients.</p>\",\"PeriodicalId\":35777,\"journal\":{\"name\":\"中国实验血液学杂志\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国实验血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.017\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.03.017","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
[The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].
Objective: To analyze the prognostic value of del(1p32) in patients with newly diagnosed multiple myeloma (MM).
Methods: The clinical data of 341 newly diagnosed MM attended in Jiangsu Province Hospital were retrospective analyzed. Clinical characteristic combined with genetic features, especially del(1p32), were analyzed for survival and prognostic of patients.
Results: Among the 341 patients with newly diagnosed MM, 24(7.0%) patients were del(1p32) positive. The progression-free survival (PFS) and overall survival (OS) were significantly shorter in MM patients with del(1p32) than those without del(1p32) (PFS: P < 0.001;OS: P < 0.001). The COX proportional-hazards model showed that del (1p32) was an independent risk factor for PFS and OS of patients with MM. The patients with both 1q21 gain/amplification and del(1p32), as "double-hit chromosome 1", have worse prognosis than those with only 1q21 gain/amplification or only del(1p32) (PFS: P < 0.001; OS: P < 0.001).
Conclusion: Del(1p32) is an independent risk factor for PFS and OS of patients with MM. Del(1p32) detection should be widely used in the prognostic analysis for newly diagnosed MM patients.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
